LONDON — BenevolentAI, a leader in AI-powered biopharmaceutical innovation, has announced a significant strategic transformation to realign the company with its foundational TechBio mission. This overhaul prioritizes core technology strengths, streamlines operations, and ensures sustainable growth through a more focused business model. Key changes include substantial cost reductions, an evaluation of delisting from Euronext Amsterdam, and a renewed commitment to delivering innovative solutions for drug discovery and development.

Returning to Foundational Strengths

The strategic shift marks a return to BenevolentAI’s original focus: integrating advanced AI to address complex challenges in biopharmaceutical development. By realigning its technologies into modular, standalone products, the company aims to provide flexible, partner-driven solutions that can be rapidly integrated across the drug development lifecycle.

Kenneth Mulvany, Executive Chairman, Founder, and activist shareholder, underscored the company’s renewed focus:
“For over a decade, BenevolentAI has pioneered AI-driven drug discovery, delivering real-world successes and transformative innovations. Our mission is to empower the biopharma industry with adaptable technologies that accelerate drug development and improve outcomes for patients. Returning to our roots means prioritizing technology in service of science, and this new roadmap reflects that vision.”

Streamlined Operations for Long-Term Viability

To support this transformation, BenevolentAI is implementing a leaner, more efficient operational structure. The company will reduce costs by reshaping its workforce and adhering to the UK Collective Consultation for Redundancy Rules and Procedures. The Board emphasized that workforce changes were considered only after thorough exploration of alternative cost-cutting measures across the organization.

These operational adjustments, combined with reduced expenditure on early-stage drug development, aim to significantly extend the company’s financial runway into 2027. The Board is also exploring the option to delist from Euronext Amsterdam to reduce administrative costs and complexity. Transitioning to a private company would enable greater operational flexibility and allow resources to be redirected toward technological advancements and commercial partnerships.

Peter Allen, Non-Executive Director and Deputy Chair, supported the decision:
“This strategy restores BenevolentAI to its TechBio roots, ensuring the company operates with entrepreneurial leadership, sharp commercial focus, and lean operations. These principles will drive sustainable growth, benefit shareholders, and deliver tangible value for partners and patients.”

Refined Partnership and Financial Strategy

BenevolentAI will continue its existing strategy of partnering on clinical-stage and pre-IND programs while reducing balance sheet risk by collaborating on earlier-stage assets sooner. This approach mitigates financial exposure while ensuring that promising discoveries progress efficiently.

The anticipated savings from cost reductions and operational efficiencies will enable the company to maintain leadership in AI-powered drug discovery and development while fostering critical partnerships.

Driving Tangible Results

BenevolentAI’s technology has already delivered measurable achievements in the biopharmaceutical sector. These include:

• Identifying a novel disease mechanism that resulted in an FDA-approved drug.
• Advancing a lead clinical candidate to Phase 2 readiness.
• Progressing two additional drug candidates toward IND readiness.
• Achieving seven milestones in its successful collaboration with AstraZeneca.

By transforming its innovations into modular, partner-ready products, BenevolentAI aims to accelerate industry adoption and support the evolving needs of biopharma partners.

Shareholder Engagement and Next Steps

BenevolentAI remains committed to transparency and will provide shareholders with detailed information on the proposed delisting process shortly.

The company’s strategic overhaul reinforces its commitment to delivering innovative AI solutions that drive meaningful advancements in drug development, benefiting shareholders, partners, and patients alike.